This article is more than 5 years old. Information may no longer be current.
Rutgers Cancer Institute of New Jersey appoints thoracic oncology chief
Click Here to Manage Email Alerts
Todd Demmy, MD, FACS, FCCP, has been appointed chief of thoracic oncology and associate chief surgical officer at Rutgers Cancer Institute of New Jersey.
Demmy is an international leader in minimally invasive thoracic surgery and one of the pioneers of video-assisted thoracoscopic surgery (VATS). His interests include studying the outcome of advanced VATS techniques and the use of regional lung chemotherapies.
Todd Demmy
Demmy most recently served as clinical chair of thoracic surgery and professor of oncology at Roswell Park Cancer Institute. He previously served as chief of thoracic oncology, co-director of cardiac transplantation and associate professor of surgery at University of Missouri Hospital and Clinics and Ellis Fischel Cancer Center.
“As the state’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey has a responsibility to recruit the most talented and accomplished professionals,” Robert S. DiPaola, MD, director of Rutgers Cancer Institute, said in a press release. “The addition of Dr. Demmy to our team demonstrates our dedication to delivering the highest quality of care for our patients and bringing internationally recognized cancer researchers to our state.”
Demmy has been recognized for advanced VATS operations, the first U.S. VATS extrapleural pneumonectomy and the world’s largest series of thoracoscopic pneumonectomies.
“Dr. Demmy’s vast experience will enhance our surgical offerings and further position Rutgers Cancer Institute of New Jersey as a leader in the treatment of thoracic cancers,” Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute, said in the press release. “His research expertise in lung cancer and advanced VATS procedures will result in additional opportunities for patients to receive the latest in cutting-edge therapies.”